Cellectar Biosciences (CLRB) announced that Jarrod Longcor, chief operating officer of Cellectar, presented positive preclinical data in a poster at the American Association for Cancer Research, AACR, Special Conference on Pancreatic Cancer Research that took place from September 28 through October 1, 2025, in Boston, Massachusetts. The poster highlighted preclinical data from CLR 121225, CLR 225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in pancreatic ductal adenocarcinoma, PDAC. CLR 225 has completed Investigational New Drug, IND,-enabling studies, and the company maintains the option to advance into a Phase 1 study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar Biosciences Raises $5.8M Through Warrant Exercise
- Cellectar Biosciences enters agreements to raise $5.8M
- EMA news ‘a substantial positive catalyst’ for Cellectar, says Oppenheimer
- Cellectar Biosciences Receives EMA Advice on Drug Filing
- Cellectar says EMA confirms eligibility to file for CMA for iopofosine I 131